22.48MMarket Cap-419P/E (TTM)
0.330High0.301Low101.74KVolume0.330Open0.319Pre Close31.99KTurnover0.19%Turnover RatioLossP/E (Static)72.48MShares2.48052wk High2.63P/B16.82MFloat Cap0.21752wk Low--Dividend TTM54.25MShs Float10.319Historical High--Div YieldTTM9.09%Amplitude0.217Historical Low0.314Avg Price1Lot Size
In8bio Stock Forum
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio presented results from their fully enrolled Phase 1 trial of INB-200 at the Society for Neuro-Oncology Annual Meeting. 50% of patients receiving repeated doses (n=10) remained alive and in remission beyond expected median overall survival, while single-dose patients (n=3) did not achieve this outcome. The trial de...
I doubled my money on this I'm happy
Love it
oh yeah let this rocket to the moooon
SEC· 18:04
No comment yet